Six‑month results from the REMAIN‑1 randomized trial showed Fractyl Health’s Revita procedure reduced weight regain after GLP‑1 discontinuation by roughly 70% versus a sham procedure. The cohort included patients who had achieved substantial weight loss on semaglutide or tirzepatide and then stopped incretin therapy. Fractyl framed the data as evidence that Revita could support weight‑loss durability after pharmacologic therapy cessation, positioning the endoscopic metabolic procedure as a complementary option in the obesity care continuum. Investors and payers will scrutinize durability beyond six months, safety, and head‑to‑head comparisons with maintenance pharmacotherapies. The outcome adds to an expanding field of device‑based metabolic interventions seeking to pair with or follow GLP‑1 therapy.